Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.

Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including among patients with non–small cell lung cancer.

ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.

Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.

Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive therapies.

Five August FDA approvals introduced novel therapies across vaccines, neurology, oncology, myeloma, and dermatomyositis, despite some regulatory pushback.

Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.

A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.